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Abstract: Nelarabine is the prodrug of 9-β-arabinofuranosylguanine (ara-G) and is 
therapeutically classified as a purine nucleoside analog. Nelarabine is converted to ara-G by 
adenosine deaminase and transported into cells by a nucleoside transporter. Ara-G is subsequently 
phosphorylated to ara-G triphosphate (ara-GTP), thereby initiating the therapeutic effect by 
inhibiting DNA synthesis. Nelarabine has been extensively studied in regards to its pharmaco-
kinetics, and the data have demonstrated that ara-GTP preferentially accumulates in malignant 
T-cells. Clinical responses to nelarabine have been demonstrated in various T-cell malignancies 
and appear to correlate with a relatively high intracellular concentration of ara-GTP compared to 
nonresponders. Therefore, this unique drug feature of nelarabine accounts for clinical utilization 
in treating adult and pediatric patients with relapsed or refractory T-cell acute lymphoblastic 
leukemia or T-cell lymphoblastic lymphoma. Neuropathy is the most predominant adverse 
effect associated with nelarabine and the incidence correlates with the dose administered. 
Myelosuppression has been observed, with thrombocytopenia and neutropenia as the most 
common hematologic complications. This article reviews the pharmacology, mechanism of 
action, and pharmacokinetic properties of nelarabine, as well as nelarabine's clinical efficacy 
in T-ALL, T-LBL, and other hematologic malignancies. The toxicity profile, dosage, and 
administration, and areas of ongoing and future research, are also presented.
Keywords: nelarabine, T-cell acute lymphoblastic leukemia, 9-beta-D-arabinofuranosyl 
guanine, ara-G
Introduction
Approximately 4000 cases of acute lymphoblastic leukemia (ALL) are diagnosed 
annually in the United States with approximately two thirds of the cases being diagnosed 
in children and adolescents between 3 to 4 years of age, making ALL the most common 
cancer within this specific population. Current pediatric chemotherapeutic regimens for 
the treatment of ALL consist of four basic phases in the treatment protocol:remission 
induction, treatment of clinical or occult centeral nervous system (CNS) disease by 
consolidation, intensification and maintenance therapy.1 Chemotherapeutic regimens 
consisting of vincristine, glucocorticoid (dexamethasone), and L-asparaginase have 
successfully induced remission in approximately 95% of children diagnosed with ALL 
leading to current long term disease-free survival rates of approximately 80%.2
Adults afflicted with ALL experience more difficulty than pediatric patients in 
terms of disease relapse as current treatment is less successful than observed in the 
pediatric patient population. Adult chemotherapeutic regimens typically consist of 
cyclophosphamide, vincristine, dexamethasone or prednisone, L-asparaginase, and an OncoTargets and Therapy 2009:2 220
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anthracycline such as doxorubicin or daunorubicin.1 Often 
methotrexate or cytarabine are used as therapeutic options 
to treat occult CNS disease.1
A challenging and more devastating subset of ALL 
includes T-cell lymphoblastic leukemia (T-ALL). Children 
diagnosed with T-ALL account for 10% to 15% of the ALL 
cases and, historically, this form of malignancy has been 
viewed as extremely difficult to treat and correlates with a 
poorer overall prognosis.1 Adults and pediatric patients with 
T-ALL have a higher rate of induction failure, early relapse 
and overt CNS relapse.
Another rare hematologic cancer is lymphoblastic 
lymphoma (LBL) and accounts for approximately 15% of 
non-Hodgkin’s lymphomas (NHL).3,4 The World Health 
Organization classifies LBL as a precursor to B-cell/T-cell 
hematologic malignancies and is considered a nodal or extra-
nodal presentation of ALL. At least 25% of bone marrow 
involvement has been considered the differentiating factor 
between LBL and ALL. The diagnosis of T-cell lympho-
blastic lymphoma (T-LBL) is more common and accounts 
for 80% of all lymphoblastic lymphomas.4 T-LBL is most 
commonly observed in children and with an appropriate 
and intensive chemotherapy regimen anticipated complete 
remission rates can be approximately 90%.4 If patients 
experience relapsed or refractory cases of LBL they have 
a poorer prognosis and treatment can become challenging. 
Therefore advancements in current therapy and management 
is essential.4
Improvements in therapeutic options available for the 
treatment of T-cell lymphoblastic leukemia and T-cell 
lymphoblastic lymphoma lead to the investigation and 
development of 9-beta-D-arabinosylguanine (ara-G) and was 
innately guided by the current role in therapy and overall suc-
cess of other purine nucleoside analogs such as cladribine, 
pentostatin, and fludarabine which are highly utilized in the 
treatment of various hematologic malignancies. Ara-G was 
initially synthesized in 1964 and was evaluated ex vivo as 
an agent that effectively eliminated malignant T cells found 
in bone marrow, but poor water solubility and difficulties 
encountered during drug synthesis significantly limited the 
drug’s use clinically.5–7 Through the use of purine arabino-
nucleoside synthesis, nelarabine was synthesized and is the 
6-methoxy derivative of ara-G, having greatly improved 
solubility making nelarabine a clinically available treatment 
modality for relapsed or refractory T-cell malignancies.
Nelarabine  is  a  nucleoside  prodrug  of  9-beta-
D-arabinofuranosyl guanine (ara-G) and was approved in 
October 2005 for the treatment of pediatric and adult patients 
diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) 
and T-cell lymphoblastic lymphoma (T-LBL) with refrac-
tory or relapsed disease following treatment with at least 
two chemotherapeutic regimens.8,9 Nelarabine was granted 
accelerated approval by the US Food and Drug Adminis-
tration (FDA) in October of 2005 based on complete and 
partial response data observed in clinical trials.9 In addition, 
nelarabine received Orphan Drug Designation since the drug 
demonstrated clinical efficacy in a specific subset of adult 
and pediatric malignancies, T-ALL and T-LBL.9
Pharmacology
Nelarabine is a substrate for adenosine deaminase and via 
demethoxylation is converted to ara-G. The conversion of 
nelarabine to ara-G is necessary to induce the active cytotoxic 
properties of nelarabine.8 Ara-G is transported intracellularly 
via nucleoside transporters where phosphorylation occurs to 
eventually convert ara-G to the active nucleotide, ara-GTP. 
The rate-limiting step is the initial phophorylation of ara-G 
to ara-GMP by deoxycytidine kinase and deoxyguanosine 
kinase.11 Triphosphorylation of ara-G to ara-GTP is essential 
for clinical activity.11 It was noted that there is a higher rate 
of phosphorylation of deoxyguanosine in T cells compared 
to B cells. Ara-G, an analog of deoxyguanosine, therefore 
preferentially accumulates in T cells.8 Ara-GTP further 
competes with deoxyguanosine triphosphate in leukemic 
blast cells for incorporation into DNA. Once ara-GTP has 
been incorporated into DNA additional DNA synthesis is 
inhibited, resulting in DNA chain termination and leukemic 
cell apoptosis.12 The specific site of incorporation into the 
leukemic cell’s DNA has not been completely characterized, 
however it is clear that incorporation into DNA in intact 
replicating cells is necessary to elicit the therapeutic and 
cytotoxic effect from nelarabine.12 The preferential accumula-
tion in T cells accounts for the drug’s clinical activity in T cell 
leukemia and lymphomas and related toxicity profile.13
Pharmacokinetics of nelarabine
The pharmacokinetics of nelarabine have been extensively 
evaluated and clearly characterized in both adult and pediatric 
patients with relapsed or refractory hematologic malignancies.8 
Nelarabine is a water soluble medication and is formulated 
for intravenous administration.8 Pharmacokinetic studies have 
determined that at the end of a 1 hour infusion of nelarabine 
concentrations were only slightly higher than concentrations 
measured at 45 minutes indicating nelarabine was approach-
ing a steady state concentration.8 The Cmax and AUC of 
nelarabine are proportional to the administered dose in the OncoTargets and Therapy 2009:2 221
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range of 5 to 75 mg/kg.8 The concentrations of nelarabine 
decline with time in a monoexponential fashion, with a half-
life of approximately 15 minutes.8 There were no statisti-
cally significant differences noted in the pharmacokinetics 
of nelarabine observed in male verses female patients or in 
patients with various hematologic malignancies including 
various leukemias.8
Pharmacokinetics of ara-G
Nelarabine is efficiently converted to ara-G, and the Cmax of 
ara-G occurs at the end of the infusion and is proportional 
to the dose of nelarabine administered. The AUC of ara-G 
is proportional to the dose of nelarabine.8 Approximately 
94% of the nelarabine dose is metabolically converted to 
ara-G during a 1 hour infusion and the AUC of ara-G is 
also proportional to the AUC of nelarabine as one mol of 
nelarabine yields one mol of ara-G after demethoxylation of 
nelarabine by adenosine deaminase.8 Peak ara-G levels are 
dependent on the dose of nelarabine administered.8
The average clearance of ara-G was found to be 
approximately 46% higher in pediatric versus adult patients. 
The increased clearance of ara-G explains in part the 30% 
shorter half-life of ara-G observed in the pediatric patient 
population compared to the adult population.8 The mean 
half-life for ara-G in pediatric patients was determined 
to be 2.1 hours as compared to 3 hours in adults.8 The 
clearance of ara-G is weakly associated with creatinine 
clearance and the dose does not need to be adjusted based 
on renal function.8 No significant differences were noted in 
volume of distribution in pediatric and adult patient popula-
tions.8 Ara-G has a relatively short half-life in both adult and 
pediatric populations, and time for elimination (greater than 
5 half-lives) of ara-G was sufficient to avoid accumulation 
after daily 1 hour infusions of nelarabine when administered 
for 5 consecutive days.8 The concentration of ara-G measured 
on days 2 through 5 during a once daily infusion were com-
parable and did not suggest accumulation over a 5-day regi-
men.8 Concentrations and pharmacokinetic parameter values 
of ara-G were evaluated in patients with different diagnoses, 
and were determined to be similar in patients with different 
hematologic malignancies.8 Related pharmacokinetic data 
are presented in Table 1.
Pharmacokinetics of ara-GTP
A range of doses of nelarabine were administered to 
19 patients (both adult and pediatric) with hematologic 
malignancies and leukemic cell concentrations of ara-GTP 
were determined. The ara-GTP median Cmax values were 
23, 42, 85, and 93 µmol/L after administration of nelarabine 
doses of 20 mg/kg, 30 mg/kg, 40 mg/kg, and 60 mg/kg.14 
Patients diagnosed with T-cell lymphoblastic leukemia had 
the highest leukemic cellular concentrations of ara-GTP 
(n = 7; median 140 µmol/L) in comparison to other hemato-
logic malignancies (n = 9; median 50 µmol/L). Accumulation 
of ara-GTP was found to be greatest in T-lymphoblastic cells 
compared to mononuclear cells (n = 3; median 30 µmol/L). 
Overall retention of ara-GTP was the greatest in T-leukemia 
cells compared to other types of leukemic cells (11 out of 
the 19 patients).14 Cellular pharmacokinetics demonstrate 
and support the concept that ara-GTP accumulates in a dose 
dependent fashion.14 The linear relationship between ara-G 
concentrations and the varying dose of nelarabine correlated 
with ara-GTP accumulation.14,16 This has been demonstrated 
both in vitro and in vivo.14,16
Clinical efficacy of nelarabine and cellular pharmacoki-
netics of ara-GTP were recently evaluated in a phase I trial 
directed by Gandhi et al with 35 patients diagnosed with 
indolent leukemias (B-cell chronic lymphocytic leukemia and 
T-cell prolymphocytic leukemia).17 Cellular concentrations 
and evidence of ara-GTP accumulation were evaluated in 25 
of the original 35 patients for the first cycle of treatment on 
days 1 through 2 of three different protocols.17 The following 
protocols were defined as: schedule A administered nelarbine 
20 to 60 mg/kg/day for 5 days, schedule B administered 
nelarabine 1.5 g/m2 to 2.9 g/m2 on days 1, 3 and 5 and 
schedule C administered nelarabine 1.2 g/m2 on days 1, 
3 and 5 with fludarabine 30 mg/m2 administered 4 hours 




  vd (L) 8.511 ± 11.518 4.197 ± 5.802 NSa
  CL (L/kg/h) 9.259 ± 12.794 5.875 ± 8.434 NSa
  t½ (minutes) 14.1b 16.5b NSa
ara-G
  vd (L) 1.023 ± 0.345 0.923 ± 0.231 NSa
  CL (L/kg/h) 0.312 ± 0.112 0.213 ± 0.072 P  0.0001
  t½ (h) 2.1b 3.0b P  0.01
ara-GTP
    Mean ara-GTP (µM) 435 ± 519 
746 ± 872c
  t½ (h) 24b,d
aNo statistical difference.
bHarmonic mean value.
cNelarabine following fludarabine (combination).
dPatient with T-cell disease.
Abbreviations: CL, clearance;   Vd, volume of distribution.OncoTargets and Therapy 2009:2 222
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prior on days 3 and 5.17 The median peak concentration for 
ara-GTP was determined to be 89 µmol/L with a range of 
22 to 1438 µmol/L.17 In order to account for the differences 
in dose and the potential effect on ara-GTP leukemic 
concentration the doses were adjusted and the median peak 
values of ara-GTP were 65 µmol/L (range 17 to 1438 µmol/L) 
which was ultimately found to be similar to the unadjusted 
values.17 The similarity in ara-GTP concentrations and 
ranges determined after dose-adjustment suggests that the 
leukemia cells may have an intrinsic ability to accumulate 
ara-GTP and that the ara-GTP concentration is not strictly 
defined by the dose administered.17 Further measures were 
taken to determine the retention of ara-GTP after peak ara-
GTP concentrations. Samples of peripheral leukemic cells 
were obtained from 13 patients and 1 patient diagnosed 
with T-cell prolymphocytic leukemia (T-PLL) demonstrated 
that the level of ara-GTP became level at 12 hours and the 
level of ara-GTP was sustained for an additional 36 hours.17 
Cellular samples evaluated after the second and third infu-
sion showed a continual increase in leukemic concentrations 
of ara-GTP.17 The median t1/2 was determined to be greater 
than 24 hours (range 9 to 42 hours) and in T-PLL and B-
CLL the t1/2 was similar and the range was 12 to 42 hours 
and 9 to 42 hours, respectively.17 Accumulation and 
retention of ara-GTP was determined to be relatively similar 
among the different treatment protocols.17
Pharmacokinetic parameters  
with co-administration  
of fludarabine and nelarabine
A pilot study combining nelarabine and fludarabine was 
designed to evaluate the biochemical modulating effects 
of fludarabine on cellular metabolism of ara-GTP and the 
relationship between clinical response and accumulation 
ara-GTP in leukemic cells.5 The presumption was the 
co-administration fludarabine with nelarabine would augment 
intracellular concentration of ara-GTP in leukemic cells that 
do not preferentially accumulate therapeutic concentrations 
of the active triphosphate such as demonstrated in B-cell 
lymphoblasts.5,14 This concept was first eluded to in an 
earlier study by Gandhi et al where the majority of clinical 
responses secondary to nelarabine were observed in patients 
diagnosed in T-cell lymphoblastic malignancies, however a 
single patient diagnosed with B-cell chronic lymphocytic 
leukemia (B-CLL) achieved a partial remission.14 The 
patient diagnosed with B-CLL had received prior treatment 
with combination cyclophosphamide and fludarabine and 
then received treatment with nelarabine therefore achieving 
greater leukemic concentrations of ara-GTP than other study 
participants diagnosed with B-cell malignancies.14
The rationale supporting the coadministration of fludara-
bine in conjunction with nelarabine is the direct inhibition of 
ribonucleotide reductase by fludarabine, resulting in increased 
ara-GTP concentrations as reflected in Table 1. It was noted 
by Gandhi et al that the increased ara-GTP concentrations in 
the face of fludarabine may be affected by residual ara-GTP 
from previous nelarabine doses.5 With the accumulation 
of fludarabine and fludarabine triphosphate (F-ara-ATP) 
there could be an overt decrease in deoxynucleotides, 
including deoxycytidine triphosphate and deoxyguanosine 
triphosphate. The overall decrease in deoxynucleotides was 
hypothesized to result in a decreased feedback inhibition of 
deoxynucleotide kinases including deoxycytidine kinase and 
deoxyguanosine kinase. Both of these kinases are involved in 
the initial phosphorpylation of ara-G to ara-GMP and would 
therefore lead to an increase in the phophorylation rate of 
ara-G to ara-GMP. This has been determined to be the rate-
limiting step in the phosphorylation cascade.11
Nelarabine at a dose of 1.2 g/m2 was administered intra-
venously on days 1, 3 and 5. Fludarabine (30 mg/m2) was 
administered intravenously over 30 minutes on days 3 and 5, 
four hours prior to the nelarabine infusion.5 Samples of 
plasma and cellular concentrations were collected during 
the initial 5 days in order to detect any differences with the 
two agents being coadministered.5
During the combination therapy of fludarabine and nelara-
bine the pharmacokinetics of ara-G were assessed on day 
one of the five day regimen, when nelarabine was administered 
as a single agent, and on a subsequent day when combined with 
fludarabine.5 The concentrations of ara-G when nelarabine 
was administered alone or in combination with fludarabine 
was similar as was the half-life of ara-G.5 The day 1 ara-G 
Cmax and AUC0-infinity were not different than day 3 values. 
Gandhi et al concluded that when fludarabine was adminis-
tered 4 hours prior to nelarabine, there was no significant 
effect on the concentrations and pharmacokinetics of ara-G.
Cellular retention and accumulation of ara-GTP levels 
were evaluated on days one through four.5 The ara-GTP 
leukemic cell elimination half-life (t1/2) was evaluated after 
48 hours. It was determined that a t1/2 greater than 35 hours 
resulted in concentrations being 45% to 100% of peak 
ara-GTP concentrations for a prolonged period, compared 
to patients with a more rapid ara-GTP elimination, with a 
t1/2 equal to 18 to 27 hours resulting in concentrations being 
17% to 27% of peak ara-GTP concentrations. It was deter-
mined that after the first and second nelarabine infusion the OncoTargets and Therapy 2009:2 223
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ara-GTP t1/2 was similar.5 Specific ara-GTP pharmacokinetics 
were compared to data obtained on day three after the 
nelarabine and fludarabine infusion. There was an observed 
increased peak in ara-GTP concentrations on day 3 compared 
to day 1; however it was difficult for the investigators to 
fully attribute this observation to the modulating effects of 
fludarabine of ara-GTP metabolism. There was accumula-
tion of ara-GTP found in the majority of patient cases which 
were attributable to previous infusions, with the residual 
percent ranging from 17% to 100% of the peak value found 
in leukemia cells. Pharmacokinetic parameters for nelarabine 
before and after administration with fludarabine were similar 
to previously reported values. Fludarabine does not influence 
an inhibitory effect on adenosine deaminase, so the initial step 
in drug conversion to the active component, ara-G, would 
not be expected to be altered.
Pharmacodynamics
Clinical response to nelarabine has been found to be 
independent of the dose of nelarabine administered.18 Gandhi 
et al characterized the cellular accumulation of ara-GTP and 
the related clinical response elicited in patients diagnosed 
with various hematologic malignancies including T-ALL, 
CML-BC (chronic myeloid leukemia, in blast crisis) and 
B-cell chronic lymphocytic leukemia. Within the study 
patients with hematologic malignancies received 20 to 
60 mg/kg of nelarabine for 5 consecutive days. The Cmax 
of ara-GTP was evaluated and determined to occur at the 
end of the infusion in 7 patients, 2 hours post-infusion 
in 8 patients and 4 hours post-infusion in the remaining 
4 patients.14 Patients who experienced a response to treatment 
with nelarabine accumulated significantly higher levels of 
ara-GTP compared to patients that failed to have a clinical 
response. The median ara-GTP concentration observed in 
7 responding patients diagnosed with T-ALL, CML-BC, 
B-CLL was 140 micromol/L versus a concentration of 
44 micromol/L in the 9 nonresponders.14
Clinical efficacy
The primary use of nelarabine is for the treatment 
of refractory hematologic malignancies. In a phase I 
study, nelarabine (506U78) was administered to patients 
with refractory hematologic malignancies in relapse to 
determine the maximum tolerated dose, related toxic-
ity, and pharmacokinetic parameter estimates of nelara-
bine. The study included 93 patients who received 1 to 
16 cycles of nelarabine as a 1 hour infusion daily for 5 
consecutive days every 21 to 28 days.18 Patients were 
stratified into 4 groups: adult leukemia (75 years of age), 
pediatric leukemia (21 years of age), adult lymphoma 
and pediatric lymphoma. Dose escalation of nelarabine 
began at 5 mg/kg/dose and was directed by protocol to 
increase doses to 10, 20, 40, 60, 75 and 90 mg/kg/dose.18 
The protocol was amended due to toxicity encountered at 
75 mg/kg/dose level.18 The amended protocol evaluated the 
adult and pediatric dose of nelarabine 1.2 gm/m2/day which 
is equivalent to an adult dose of 40 mg/kg and a pediatric 
dose of 60 mg/kg. Of the 93 patients enrolled 59 were adults 
and 34 were children.18 A total of 66% of patients had T-cell 
malignancies, 22% had B-cell malignancies, and 13% had 
myeloid or other hematologic malignancies. The majority of 
patients enrolled in the study experienced treatment failure 
with at least 2 prior therapies for their disease with a median 
number of 3 prior regimens.18 Twenty-seven patients received 
a previous bone marrow transplant, 39 patients received 
total body irradiation, 14 received cranial or craniospinal 
irradiation and 45 received intrathecal chemotherapy for treat-
ment of disease within the CNS. Thirty-nine patients (42%) 
were diagnosed with T-lymphoid disease including acute 
lymphoblastic leukemia or lymphoblastic lymphoma.
In T-lymphoid lineage malignancies (T-cell acute 
lymphoblastic leukemia and T-cell lymphoblastic lymphoma) 
a total of 23% (n = 9/39) of both adult and pediatric patients 
achieved a complete response. In the pediatric subgroup, 27% 
(n = 7/26) of the patients had a complete response and 15% 
(n = 2/13) of adults had a complete response.18 Of the 23% 
of complete responders 2 patients were removed from the 
study to pursue a second bone marrow transplant, with 1 of 
these patients surviving in complete remission 4 years after 
mismatched cord blood transplantation.18 The other patient 
died in remission secondary to graft-versus-host disease 
(GVHD) 3 months post-transplantation. Partial responses 
were observed in 31% (12/39) of both adult and pediatric 
populations with 71% (n = 15/21) responders having 
experienced 2 or more relapses and 48% (n = 10/21) having 
had treatment failure with a prior bone marrow transplanta-
tion.18 Complete responses and partial responses observed 
within the T-lymphoid lineages occurred at multiple dose 
levels of nelarabine. Another patient with chronic myeloid 
leukemia in lymphoid blast crisis that had experienced 
treatment failure with 2 prior induction regimens prior to 
study enrollment achieved a complete response for 57 weeks 
and then experienced disease relapse within the CNS.18
Responses were seen in 30% (3/10) of patients with 
T- or B-cell lineage CLL (partial remission).18 One patient 
with prolymphocytic leukemia experienced hematologic OncoTargets and Therapy 2009:2 224
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improvement after receiving treatment during the study with 
nelarabine. Patients considered being refractory to other 
nucleoside analogs including cytarabine, fludarabine and 
pentostatin responded to treatment with nelarabine.18
The maximum tolerated dose of nelarabine administered 
daily over 1 hour for 5 consecutive days was determined to be 
60 mg/kg/dose for children and 40 mg/kg/dose for adults.18 
When evaluating the overall results of the study across all 
diagnoses and both adult and pediatric populations (n = 93), 
11% (n = 10) achieved a complete response, 20% (n = 19) 
had a partial response and 49% (n = 46) had a hematological 
improvement, stable disease, no response or disease progres-
sion.18 The remaining 19% (n = 18) of the patient population 
were considered nonassessable for response due to: hypocel-
lular bone marrow (n = 1), incomplete bone marrow/tumor 
evaluation at maximal clinical response (n = 7), death before 
21 days (not attributable to the study drug) (n = 9) and 
removal from the study secondary to adverse events before 
21 days (n = 1).18
In summary, complete and partial responses were observed 
in 54% (n = 21/39) of both adult and pediatric patients with 
T-cell acute lymphoblastic leukemia or T-cell acute lympho-
blastic lymphoma after 1 to 2 courses of therapy.18
Another trial conducted by the Cancer and Leukemia 
Group B evaluated the efficacy and safety of nelarabine in 
patients diagnosed with either T-cell acute lymphoblastic 
leukemia (T-ALL) or T-cell lymphoblastic lymphoma 
(T-LBL). The patient population consisted of 40 patients 
with a total of 39 receiving at least 1 dose of nelarabine. 
The population comprised 32 males and 7 females, ranging 
in age from 16 to 66 years with a median age of 34 years.15 
A total of 26 patients were diagnosed with T-ALL and 
13 with T-LBL. All patients enrolled were refractory or 
had relapsed to at least 1 induction regimen after achieving 
a complete response to prior chemotherapy treatment. The 
majority of the patient population had an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0 (n = 11) 
or 1 (n = 17).15 Both groups of patients received nelarabine 
1.5 g/m2 on days 1, 3 and 5 and repeated this regimen for a 
total of 2 induction cycles.15 The patients who achieved a com-
plete remission after receiving treatment with nelarabine were 
permitted to receive an additional 2 courses of therapy.15
From the initial 40 patients enrolled, 39 patients were 
evaluated after receiving at least 1 treatment dose of nelarabine 
with 26 patients (67%) having T-ALL and 13 patients 
(33%) having T-LBL.15 A total of 31% patients (n = 8) 
with T-ALL achieved a complete remission with or without 
hematopoietic recovery with another 31% of patients (n = 4) 
diagnosed with T-LBL achieved a complete remission.15 
A total of 28 patient had received at least 2 prior induction 
regimens before receiving nelarabine. Of these 28 patients, 
36% (n = 10) experienced a complete, incomplete or a par-
tial remission when treated with nelarabine. The remaining 
patient population (n = 11) had received only 1 prior induc-
tion regimen, 55% (n = 6) achieved a complete, incomplete 
or a partial remission when treated with nelarabine.15
A total of 10 patients (26%) achieved a complete 
remission for a median duration of 27 weeks.15 A total of 41% 
(n = 16) achieved either a complete or partial remission to 
treatment with nelarabine. The median survival for patients 
with 1 prior induction regimen was 20 weeks (95% CI 12-219 
weeks) with the median survival for 2 prior induction regi-
mens as 20 weeks (95% CI 10 to 36 weeks).15 Based upon 
the response in this trial the investigators concluded that the 
1-year disease-free survival for all patients was 28%.15
The National Cancer Institute sponsored a Phase II 
study at MD Anderson Cancer Center (MDACC) which 
evaluated nelarabine therapy in patients diagnosed with 
non-Hodgkin’s lymphoma. The study population consisted 
of 23 patients, 17 males and 6 females, within the age 
range of 33 to 81 years.19 The patient population consisted 
of 13 patients diagnosed with peripheral T-cell lymphoma 
and 10 patients diagnosed with low-grade B-cell lym-
phoma and both groups were considered relapsed and/or 
refractory secondary to failure of 1 to 3 previous chemo-
therapy regimens.19 Nelarabine 1.5 g/m2 was administered 
intravenously on an alternate day regimen on days 1, 3 and 5 
and was repeated every 28 days for a total of 6 cycles.19 The 
study regimen was held in the presence of  disease progres-
sion or toxicity. The average number of cycles received by 
the study participants was 3.1 cycles.19
Eight out of the 13 patients diagnosed with peripheral 
T-cell lymphoma were evaluable, and 2 patients in this 
group died (unrelated to treatment with nelarabine) and 
2 patients were in the early stages of the nelarabine regimen 
and 1 patient was removed from the study secondary to 
adverse events.19 Overall, 50% of the patients diagnosed 
with peripheral T-cell lymphoma achieved either a complete 
(n = 2/8) or a partial (n = 2/8) response.19 Overall, 9 out of 
the 10 patients with low-grade B-cell lymphoma a total of 
44% of patients (n = 4) experienced a partial response.19 
The remaining patients either had stable disease or disease 
progression while receiving nelarabine.19
A Phase 2 study was sponsored by The Pediatric 
Oncology Group/Children’s Cancer Group (POG/CCG), 
which evaluated the response to nelarabine in patients with OncoTargets and Therapy 2009:2 225
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refractory T-cell hematologic malignancies or non-Hodgkin’s 
lymphoma. The study population consisted of children 
(21 years of age) with refractory or recurrent T-cell acute 
lymphoblastic leukemia or non-Hodgkin’s lymphoma.20 
This study population was stratified into 1 of 4 groups based 
upon the following classification: 1) patients refractory to 
initial induction therapy or 25% bone marrow blasts in 
first relapse; 2) patients with 25% bone marrow blasts 
in second or greater relapse; 3) patients with positive 
cerebrospinal fluid and 5% bone marrow blasts; 4) patients 
with extramedullary relapse and 25% bone marrow 
blasts. Nelarabine 1.2 g/m2 was administered intravenously 
over 60 minutes for 5 consecutive days every 3 weeks.20 This 
dose was adjusted in Groups 1 and 2 to 650 mg/m2 second-
ary to neurotoxic adverse events.20 The patients in Groups 3 
and 4 received nelarabine 400 mg/m2. A total of 153 patients 
were initially enrolled and 121 were enrolled at the final dose 
levels and 106 patients were evaluable, with 33 patients in 
Group 1, 30 patients in group 2, 21 patients in group 3, and 
22 patients in group 4.20 The responses to nelarabine were as 
follows: Group 1, 18 patients responded to nelarabine with 
48% (n = 16/33) achieving a complete response and 6% 
(n = 2) experienced a partial response; Group 2 had a total 
of 23% of patients (n = 7/30) achieving a complete response 
and 3% (n = 1/30) had a partial response; Group 3, overall 
24% (n = 5/21) experienced a complete response and 10% 
(n = 2/20) had a partial response; Group 4, 14% (n = 3/22) 
achieved a partial response to treatment with nelarabine.20
This Phase 2 study clearly demonstrated that nelarabine 
is a viable treatment option for patients diagnosed with 
relapsed or refractory T-cell malignancies, with the strongest 
clinical results found in patients with T-cell leukemia in 
first relapse.20 Overall, of the 106 patients evaluated, 26% 
(n = 28/106) had a complete response and 8% (n = 9/106) had 
a partial response.20 Of note, a total of 8 out of 22 patients 
that had a positive lumbar puncture for CSF disease prior 
to nelarabine administration had negative lumbar puncture 
for CSF disease only 7 days after the initiation of nelarabine 
treatment regimen. These responses occurred prior to any 
intrathecal treatment.20
Safety
Overall tolerability of nelarabine during a phase I trial by 
Kurtzberg et al was related to dose limiting neurotoxicity 
that was often reversible upon drug discontinuation or 
dose reduction. The incidence of neurologic toxicity was 
correlated to the dose of nelarabine received with more 
severe neurotoxicity occurring more frequently in patients 
receiving higher doses of nelarabine.18 However the severity 
of the neurotoxicity experienced cannot be reliably correlated 
with the dose of nelarabine administered, as adult and 
pediatric patients receiving modest doses (10 mg/kg/day 
and 20 mg/kg/day) experienced similar neurotoxicity such 
as somnolence, malaise and fatigue, as adults and pediatric 
patients receiving higher doses of nelarabine (40 mg/kg/day 
and 60 mg/kg/day).18
Neurologic adverse events directly attributable to 
nelarabine occurred in 72% (n = 67/93) patients enrolled 
in this phase I trial.18 Approximately half of the children 
enrolled and 85% of the adults experienced reversible 
neurotoxicity secondary to receiving the study drug.18 
Symptom presentation began with transient somnolence, 
malaise with overt fatigue predominantly occurring 6 to 
8 days after the initiation of the nelarabine regimen, while 
the onset of neurotoxicity symptoms generally appeared 
12 days post-regimen initiation.18 Both central and 
peripheral toxicities were reported. While there were no 
documented delayed or latent neurotoxicities observed 
the study was not designed for follow-up in terms of 
medication-related toxicities.18
A total of 11 patients treated with higher doses of 
nelarabine (1.2 g/m2 or 40 mg/kg and 60 mg/kg in adult and 
pediatric patients, respectively) experienced cumulative 
neurotoxicity depicted as hypoesthesias, paresthesias or 
peripheral neuropathies.18 Within this group 3/11 patients 
experienced a severe grade of neurotoxicity with 4/11 
remaining unresolved at the end of the study. One pediatric 
patient diagnosed with T-cell acute lymphoblastic leukemia 
in refractory relapse experienced severe and irreversible 
neurotoxicity after receiving treatment with 75 mg/kg/day 
of nelarabine.18 Approximately 12 days after initiating the 
treatment regimen this pediatric patient experienced seizures, 
myoclonic jerks, ascending paralysis and coma resulting 
eventually in death. The overall neurotoxicity was extensive, 
requiring mechanical ventilation and the patient did not 
regain full consciousness.
Although a significant portion of patients enrolled in 
the phase I trial experienced dose limiting neurotoxicity, 
the patients had concomitant factors for the development 
of neurotoxicity.18 Of these 11 patients treated with higher 
doses of nelarabine, 8 had received prior therapy with 
vincristine which could have contributed to the development 
of neurotoxicity.18 However, 70 other patients within the 
study had received prior therapy with vincristine (1 month 
prior to study enrollment) and did not develop cumulative 
neurotoxicity. Furthermore, 73% of patients previously OncoTargets and Therapy 2009:2 226
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treated with high dose cytarabine, 71% previously treated 
with vincristine, 60% having received intrathecal therapy, 
53% with prior radiation therapy and 67% with presence 
of leukemic disease in the CSF at the time of treatment 
all experienced neurotoxicity independent of the dose of 
nelarabine administered.18 In addition, all patients of at least 
60 years of age experienced neurotoxicity.
Evaluating the hematologic impact of nelarabine, a total 
of 77 (83%) patients had documented disease in the bone 
marrow upon entry into the study and made hematologic 
toxicities difficult to accurately quantify.18 Hematologic 
toxicities observed in the phase I trial by Kurtzberg et al 
included Grade 1 and 2 neutropenia and thrombocytopenia 
in 50% and 76% of pediatric patients, respectively and 46% 
and 42% of adult patients, respectively. In patients who 
achieved a documented complete response or had no docu-
mented bone marrow involvement, there was no Grade 3 or 4 
hematologic toxicities.18 At the conclusion of the study, 
hematologic toxicities were determined not to be cumulative 
or dose limiting.
The most common nonneurologic and nonhematologic 
toxicities encountered affected 70% of the study popula-
tion and included nausea, vomiting, diarrhea, fever, and 
anorexia.18 The occurrences of these toxicities were observed 
more frequently in adults compared to children. Complica-
tions secondary to these toxicities were not noted in any adult 
or pediatric patient.18
In the CALGB phase II trial safety and toxicity infor-
mation was available for 38 of the 39 patients enrolled 
in the study.15A total of 14 patients (37%) experienced 
grade 1 or 2 peripheral sensory neuropathy and 8 patients 
(21%) experienced peripheral motor neuropathy, only 
1 case being identified as grade 3.15 Two patients withdrew 
from the study after experiencing grade 3 and 4 peripheral 
sensory neuropathy.15 During the study 1 patient who 
had been treated with a cumulative dose of 4.5 g/m2 of 
nelarabine experienced a grade 3 seizure; however this 
event was thought to be secondary to imipenem and renal 
dysfunction.15 There was only 1 case of a grade 4 neurologic 
toxicity which was noted as a reversible depressed level of 
consciousness. No patient deaths were linked to the protocol 
or treatment with nelarabine.15
Nonhematologic events encountered during the CALGB 
trial were classified as a grade 3 or higher toxicity and 
included fatigue (n = 7) and muscle weakness (n = 4).15 
Gastrointestinal complaints were noted in 51% of the patients 
and included nausea, vomiting, diarrhea, and stomatitis, 
however only one of the events was classified as severe 
(grade 3 diarrhea).15 Hematologic toxicities encountered 
were grade 3 and 4 and were predominantly neutropenia and 
thrombocytopenia. Grade 3 neutropenia was experienced by 
a total of 5 patients (13%) with 11 patients classified with 
grade 4 neutropenia.15 Thrombocytopenia of grade 3 and 4 
was experienced by 7 patients (18%) and 6 patients (16%), 
respectively.15
Adverse events encountered in the MDACC study 
also included neurotoxicities secondary to nelarabine 
administration. Out of 23 patients enrolled, there were 
2 grade 3/4 neurotoxic adverse events. One patient 
experienced sensory neuropathy following the sixth cycle 
of nelarabine, and the second patient developed ascending 
sensory and motor polyneuropathy during the initial cycle 
of therapy.19 Additionally, one other patient experienced 
central nervous system toxicity, described as acute onset 
of confusion which resolved within 48 hours. Throughout 
the remainder of the study there were no other high grade 
or intolerable adverse events noted. The only additional 
adverse events encountered included a grade 3 myalgia 
(n = 1), grade 3/4 infection (n = 3) and grade 3 diarrhea 
(n = 1). For hematologic toxicities, 1 patient had neutropenia 
and 1 patient had grade 3 thrombocytopenia.19
The POG/CCG trial also encountered neurotoxic adverse 
effects secondary to treatment with nelarabine. All children 
who received at least 1 dose of nelarabine were evaluated 
for potential neurotoxic adverse effects (n = 151).20 A total 
of 18% (n = 27) of enrolled patients experienced either a 
grade 3 or 4 neurotoxicity, although not all events were 
entirely attributable to the administration of nelarabine.20 
Patients that received nelarabine 400 mg/m2/day for 5 con-
secutive days (n = 50) resulted in a total of 17 grade 3/4 
neurologic toxicities, 6 being peripheral in origin.20 Patients 
that received nelarabine 650 mg/m2/day for 5 consecutive 
days (84) resulted in 10 patients experiencing a grade 3/4 
neurologic toxicity.20 Finally, 4 patients receiving nelarabine 
900 mg/m2/day for 5 consecutive days experienced a grade 
3/4 neurologic toxicity and 2 grade 3/4 peripheral nervous 
system toxicity. Tables 2 and 3 contain cumulative data 
presented by the US FDA Oncology Drugs Advisory 
Committee (ODAC) regarding the prevalence of neurotoxic-
ity in patients treated with nelarabine.
The potential neurotoxicity induced by nelarabine appears 
to have both modest and severe symptom presentation and 
has been reported as reversible in several cases.15,17,18 Patients 
who experienced the neurotoxic effect often had received 
prior therapy with a different chemotherapeutic agent that 
also has the potential to induce neurotoxicity, and the status OncoTargets and Therapy 2009:2 227
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of the patients hematologic malignancy was either relapsed 
or refractory prior to treatment with nelarabine.15,18 For all 
therapeutic modalities the risk versus the benefit of every 
option should be considered prior to therapeutic initiation.
Future research
Nelarabine has been primarily evaluated in adult and pediatric 
patients diagnosed with T-cell lymphoblastic lymphoma or 
leukemia whose disease is refractory or has relapsed while 
receiving treatment with other chemotherapeutic regimens. 
The potential role of nelarabine as a first-line option in 
patients diagnosed with T-cell malignancies has not been 
extensively evaluated and presents an opportunity for future 
research and development.
Current clinical trials have evaluated the safety and 
efficacy of nelarabine as a single agent administered 
as monotherapy. Although nelarabine was studied in 
combination with fludarabine as a potential option to 
increase intracellular concentrations of the clinically active 
moiety, ara-GTP, combination with other chemotherapeutic 
agents has not been extensively evaluted.2 Combination or 
substitution of nelarabine in chemotherapy regimens that 
contain nucleoside analogs are potential opportunities of 
evaluation.15,16
Conclusion
Nelarabine, a nucleoside analog, has been approved for 
the treatment of adult or pediatric T-cell lymphoblastic 
leukemia or lymphoma that is relapsed or refractory to two 
or more chemotherapeutic regimens. As demonstrated in 
clinical trials, nelarabine has proven to be a viable option for 
patients who have failed other chemotherapeutic regimens. 
Nelarabine has a distinct role and place in current therapy, 
and with further research and investigation may also have a 
role in combination with other chemotherapy.
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